Performance of rotavirus vaccines in developed and developing countries

References

• Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200:9 - 15
   PubMed Web of Science ®Google Scholar
• Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerging infectious diseases 2006; 12:304 - 306
   PubMed Web of Science ®Google Scholar
• Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerging infectious diseases 2003; 9:565 - 572
   PubMed Web of Science ®Google Scholar
• Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H, Espinoza F, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181 - 1189
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11 - 22
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757 - 1763
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23 - 33
   PubMed Web of Science ®Google Scholar
• WHO. Meeting of the immunization Strategic Advisory Group of Experts, April 2009—conclusions and recommendations. Wkly Epidemiol Rec 2009; 84:220 - 236
   PubMedGoogle Scholar
• WHO. Rotavirus vaccines. Wkly Epidemiol Rec 2007; 82:285 - 295
   PubMedGoogle Scholar
• Patel MM, Parashar UD. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. J Infect Dis 2009; 200:291 - 299
   PubMed Web of Science ®Google Scholar
• Bishop RF, Davidson GP, Holmes IH, Ruck BJ. Detection of a new virus by electron microscopy of faecal extracts from children with acute gastroenteritis. Lancet 1974; 1:149 - 151
   PubMed Web of Science ®Google Scholar
• Estes MK, Cohen J. Rotavirus gene structure and function. Microbiol Rev 1989; 53:410 - 449
   PubMedGoogle Scholar
• Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 2005; 192:146 - 159
   PubMed Web of Science ®Google Scholar
• Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006; 24:2718 - 2731
   PubMed Web of Science ®Google Scholar
• Ward R. Mechanisms of protection against rotavirus infection and disease. Pediatr Infect Dis J 2009; 28:57 - 59
   PubMed Web of Science ®Google Scholar
• Green KY, Taniguchi K, Mackow ER, Kapikian AZ. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. J Infect Dis 1990; 161:667 - 679
   PubMed Web of Science ®Google Scholar
• Rojas AM, Boher Y, Guntinas MJ, Perez-Schael I. Homotypic immune response to primary infection with rotavirus serotype G1. J Med Virol 1995; 47:404 - 409
   PubMed Web of Science ®Google Scholar
• Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999; 17:2207 - 2222
   PubMed Web of Science ®Google Scholar
• Bresee JS, Parashar UD, Widdowson MA, Gentsch JR, Steele AD, Glass RI. Update on rotavirus vaccines. Pediatr Infect Dis J 2005; 24:947 - 952
   PubMed Web of Science ®Google Scholar
• Vesikari T, Isolauri E, D'Hondt E, Delem A, Andre FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984; 1:977 - 981
   PubMed Web of Science ®Google Scholar
• Vesikari T, Isolauri E, Delem A, d'Hondt E, Andre FE, Beards GM, et al. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr 1985; 107:189 - 194
   PubMed Web of Science ®Google Scholar
• Ruuska T, Vesikari T, Delem A, Andre FE, Beards GM, Flewett TH. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. Scand J Infect Dis 1990; 22:269 - 278
   PubMed Web of Science ®Google Scholar
• Vesikari T, Ruuska T, Delem A, Andre FE, Beards GM, Flewett TH. Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea. Acta Paediatr Scand 1991; 80:173 - 180
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Clark HF, Pichichero M, Christy C, Gouvea V, Shrager D, et al. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatr Infect Dis J 1995; 14:301 - 307
   PubMed Web of Science ®Google Scholar
• Christy C, Madore HP, Pichichero ME, Gala C, Pincus P, Vosefski D, et al. Field trial of rhesus rotavirus vaccine in infants. Pediatr Infect Dis J 1988; 7:645 - 650
   PubMed Web of Science ®Google Scholar
• Vesikari T, Rautanen T, Varis T, Beards GM, Kapikian AZ. Rhesus Rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age. Am J Dis Child 1990; 144:285 - 289
   PubMedGoogle Scholar
• Perez-Schael I, Garcia D, Gonzalez M, Gonzalez R, Daoud N, Perez M, et al. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. J Med Virol 1990; 30:219 - 229
   PubMed Web of Science ®Google Scholar
• De Mol P, Zissis G, Butzler JP, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986; 2:108 - 108
   PubMed Web of Science ®Google Scholar
• Hanlon P, Hanlon L, Marsh V, Byass P, Shenton F, Hassan-King M, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987; 1:1342 - 1345
   PubMed Web of Science ®Google Scholar
• Lanata CF, Black RE, del Aguila R, Gil A, Verastegui H, Gerna G, et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989; 159:452 - 459
   PubMed Web of Science ®Google Scholar
• Santosham M, Letson GW, Wolff M, Reid R, Gahagan S, Adams R, et al. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. J Infect Dis 1991; 163:483 - 487
   PubMed Web of Science ®Google Scholar
• Lanata CF, Black RE, Flores J, Lazo F, Butron B, Linares A, et al. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru. Vaccine 1996; 14:237 - 243
   PubMed Web of Science ®Google Scholar
• Georges-Courbot MC, Monges J, Siopathis MR, Roungou JB, Gresenguet G, Bellec L, et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 1991; 142:405 - 411
   PubMedGoogle Scholar
• Midthun K, Kapikian AZ. Rotavirus vaccines: an overview. Clin Microbiol Rev 1996; 9:423 - 434
   PubMed Web of Science ®Google Scholar
• Stuker G, Oshiro LS, Schmidt NJ. Antigenic comparisons of two new rotaviruses from rhesus monkeys. J Clin Microbiol 1980; 11:202 - 203
   PubMed Web of Science ®Google Scholar
• Ukae S, Nakata S, Adachi N, Kogawa K, Chiba S. Efficacy of rhesus rotavirus vaccine MMU-18006 against gastroenteritis due to serotype 1 rotavirus. Vaccine 1994; 12:933 - 939
   PubMed Web of Science ®Google Scholar
• Clark HF, Offit PA, Ellis RW, Eiden JJ, Krah D, Shaw AR, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996; 174:73 - 80
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA. US Rotavirus Vaccine Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. Jama 1995; 273:1191 - 1196
   PubMed Web of Science ®Google Scholar
• Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, et al. United States Rotavirus Vaccine Efficacy Group. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines—report of the National Multicenter Trial. Pediatrics 1996; 97:7 - 13
   PubMed Web of Science ®Google Scholar
• Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350:1205 - 1209
   PubMed Web of Science ®Google Scholar
• Linhares AC, Gabbay YB, Mascarenhas JD, de Freitas RB, Oliveira CS, Bellesi N, et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull World Health Organ 1996; 74:491 - 500
   PubMed Web of Science ®Google Scholar
• Perez-Schael I, Guntinas MJ, Perez M, Pagone V, Rojas AM, Gonzalez R, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 337:1181 - 1187
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23:937 - 943
   PubMed Web of Science ®Google Scholar
• Salinas B, Perez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzabal JP, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24:807 - 816
   PubMed Web of Science ®Google Scholar
• Araujo EC, Clemens SA, Oliveira CS, Justino MC, Rubio P, Gabbay YB, et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de pediatria 2007; 83:217 - 224
   PubMed Web of Science ®Google Scholar
• Clark HF, Bernstein DI, Dennehy PH, Offit P, Pichichero M, Treanor J, et al. Safety, efficacy and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004; 144:184 - 190
   PubMed Web of Science ®Google Scholar
• Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Coia M, et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis 2007; 11:29 - 35
   PubMed Web of Science ®Google Scholar
• Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med; 362:289 - 298
   PubMed Web of Science ®Google Scholar
• Santosham M, Moulton LH, Reid R, Croll J, Weatherholt R, Ward R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997; 131:632 - 638
   PubMed Web of Science ®Google Scholar
• Lanata CF, Midthun K, Black RE, Butron B, Huapaya A, Penny ME, et al. Safety, immunogenicity and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996; 174:268 - 275
   PubMed Web of Science ®Google Scholar
• Linhares AC, Lanata CF, Hausdorff WP, Gabbay YB, Black RE. Reappraisal of the Peruvian and Brazilian lower titer tetravalent rhesus-human reassortant rotavirus vaccine efficacy trials: analysis by severity of diarrhea. Pediatr Infect Dis J 1999; 18:1001 - 1006
   PubMed Web of Science ®Google Scholar
• Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564 - 572
   PubMed Web of Science ®Google Scholar
• Patel MM, Haber P, Baggs J, Zuber P, Bines JE, Parashar UD. Intussusception and rotavirus vaccination: a review of the available evidence. Expert review of vaccines 2009; 8:1555 - 1564
   PubMed Web of Science ®Google Scholar
• WHO. Meeting of the Strategic Advisory Group of Experts on immunization, October 2009—conclusions and recommendations. Wkly Epidemiol Rec 2009; 84:518 - 518
   Google Scholar
• Macartney KK, Burgess MA. Rapid impact of rotavirus vaccination in the United States: implications for Australia. Med J Aust 2009; 191:131 - 132
   PubMed Web of Science ®Google Scholar
• Orozco M, Vasquez J, Pedreira C, De Oliveira LH, Amador JJ, Malespin O, et al. Uptake of rotavirus vaccine and national trends of acute gastroenteritis among children in Nicaragua. J Infect Dis 2009; 200:125 - 130
   PubMedGoogle Scholar
• Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, Fowlkes AL, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009; 124:465 - 471
   PubMed Web of Science ®Google Scholar
• Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243 - 2251
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Ward RL. Rotarix: development of a live attenuated monovalent human rotavirus vaccine. Pediatr Ann 2006; 35:38 - 43
   PubMed Web of Science ®Google Scholar
• Cunliffe NA, Kirsten M, Madhi S, et al. Efficacy of human rotavirus vaccine RIx4414 in Africa during the first year of life 2009; Presented at the 26th meeting of the European Society of Pediatric Infectious Diseases June 9–13, 2009 Brussels, Belgium
   Google Scholar
• de Oliveira LH, Danovaro-Holliday MC, Matus CR, Andrus JK. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert review of vaccines 2008; 7:345 - 353
   PubMed Web of Science ®Google Scholar
• Nakagomi T, Patel M, Nakagomi O, Cunliffe NA, Parashar U, et al. Effectiveness of a monovalent G1P[8] human rotavirus vaccine against severe diarrhea caused by heterotypci G2P[4] rotavirus strains in Recife, Brazil 2009; Presented at the 26th meeting of the European Society of Pediatric Infectious Diseases June 9–13, 2009 Brussels, Belgium
   Google Scholar
• Snelling TL, Andrews RM, Kirkwood CD, Carapetis JR. Evaluation of the Monovalent Human Rotavirus Vaccine RIX4414 following a G2P[4] Outbreak 2009; Presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) San Francisco CA, USA
   Google Scholar
• Snelling TL, Schultz R, Graham J, Roseby R, Barnes GL, Andrews RM, et al. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin Infect Dis 2009; 49:428 - 431
   PubMed Web of Science ®Google Scholar
• WHO. Generic protocol for monitoring impact of rotavirus vaccination on rotavirus disease burden and viral strains. Document WHO/IVB/0816 Geneva 2009; 1 - 73
   Google Scholar
• Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq E, Forster J, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004; 22:2836 - 2842
   PubMed Web of Science ®Google Scholar
• Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, et al. Human rotavirus vaccine RIX4414 is highly efficacious in Asian infants during the third year of life 2009; Presented at the 26th meeting of the European Society of Pediatric Infectious Diseases, P608 June 9–13, 2009 Brussels, Belgium
   Google Scholar
• Vesikari T, Karvonen A, Allen S, Lawrence J, Ciarlet M. Serotype-specific efficacy of the pentavalent rotavirus vaccine against hospitalizations and emergency department visits up to three years [abstract] Presented at: the 48th ICAAC/46th IDSA Annual Meeting October 25–28, 2008 Washington DC
   Google Scholar
• Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006; 368:323 - 332
   PubMed Web of Science ®Google Scholar
• Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005; 192:160 - 166
   PubMed Web of Science ®Google Scholar
• Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most?. J Infect Dis 2009; 200:39 - 48
   PubMed Web of Science ®Google Scholar
• Danchin MH, Bines JE. Defeating rotavirus? The global recommendation for rotavirus vaccination. N Engl J Med 2009; 361:1919 - 1921
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, Losonsky G, et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 1993; 61:3994 - 3997
   PubMed Web of Science ®Google Scholar
• Hallander HO, Paniagua M, Espinoza F, Askelof P, Corrales E, Ringman M, et al. Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children. Vaccine 2002; 21:138 - 145
   PubMed Web of Science ®Google Scholar
• Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, Abrego P, et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 1999; 180:1709 - 1712
   PubMed Web of Science ®Google Scholar
• Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009; 361:335 - 344
   PubMed Web of Science ®Google Scholar
• Grassly NC, Jafari H, Bahl S, Durrani S, Wenger J, Sutter RW, et al. Mucosal Immunity after Vaccination with Monovalent and Trivalent Oral Poliovirus Vaccine in India. J Infect Dis 2009;
   PubMed Web of Science ®Google Scholar
• Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926 - 939
   PubMedGoogle Scholar
• Jiang B, Gentsch JR, Glass RI. Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine 2008; 26:6754 - 6758
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Simonsen L, Vesikari T, Hoshino Y, Morens DM, Chanock RM, et al. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J Infect Dis 2005; 192:22 - 29
   PubMed Web of Science ®Google Scholar
• Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993; 168:282 - 287
   PubMed Web of Science ®Google Scholar
• Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983; 309:72 - 76
   PubMed Web of Science ®Google Scholar
• Chiba S, Yokoyama T, Nakata S, Morita Y, Urasawa T, Taniguchi K, et al. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet 1986; 2:417 - 421
   PubMed Web of Science ®Google Scholar
• Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022 - 1028
   PubMed Web of Science ®Google Scholar
• Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259 - 267
   PubMed Web of Science ®Google Scholar
• 2010 Available at http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK: 20420458∼menuPK:64133156∼pagePK:64133150∼piPK:64133175∼theSitePK:239419,00.html
   Google Scholar
• Boom J, Tate JE, Sahni L, Rench M, Patel M, Baker C, et al. Effectiveness of Pentavalent Rotavirus Vaccine in a Large Urban Population in the United States. Pediatrics In press January 2009.
   Web of Science ®Google Scholar
• Payne DC, Staat MA, Szilagyi PG, Edwards K, Gentsch J, Weinberg GA, et al. Decline in rotavirus hospitalizations in 3 U.S. counties after introduction of rotavirus vaccine 2009; Paper presented at: Pediatric Academic Societies Conference May 2–5, 2009 Baltimore, MD
   Google Scholar
• WHO. Report of the meeting on future direction for rotavirus vaccine research in developing countries.. Geneva: World Health Organization. Document WHO/V & B/00.23 2000; 1 - 56
   Google Scholar